<DOC>
	<DOCNO>NCT01320683</DOCNO>
	<brief_summary>This phase II trial study well give combination chemotherapy bevacizumab surgery radiolabeled monoclonal antibody therapy work treat liver metastases patient metastatic colorectal cancer . Drugs use chemotherapy , leucovorin calcium , fluorouracil , oxaliplatin ( FOLFOX ) , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiolabeled monoclonal antibody , yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A , find tumor cell carry tumor-killing substance without harm normal cell . Giving chemotherapy monoclonal antibody surgery may make tumor small reduce amount normal tissue need remove . Giving radiolabeled monoclonal antibody therapy surgery may kill tumor cell remain surgery</brief_summary>
	<brief_title>Combination Chemotherapy Bevacizumab Before Surgery Radiolabeled Monoclonal Antibody Therapy Treating Liver Metastases Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine progression free survival colorectal cancer patient hepatic resection liver metastases FOLFOX leucovorin calcium , fluorouracil , irinotecan hydrochloride ( FOLFIRI ) chemotherapy [ +/- Bevacizumab ] , capecitabine oxaliplatin ( XELOX ) , follow intravenous ( IV ) yttrium-90 ( 90Y ) M5A anti-CEA antibody . SECONDARY OBJECTIVES : I . To study feasibility toxicity adjuvant therapy follow resection and/or ablation liver metastases FOLFOX chemotherapy . II . To evaluate biodistribution , clearance metabolism 90Y 111In ( indium-111 ) M5A administer IV . OUTLINE : FOLFOX* + BEVACIZUMAB CHEMOTHERAPY : Patients receive oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour , fluorouracil IV continuously 46-48 hour , bevacizumab IV 30-90 minute . Treatment repeat 12 course absence disease progression unacceptable toxicity . RADIOIMMUNOTHERAPY ( RIT ) : Within 4-12 week completion post-hepatic resection therapy chemotherapy , patient receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV 25 minute . Treatment repeat every 6-10 week 2 course absence disease progression unacceptable toxicity . NOTE : *Patients previously fail oxaliplatin regimen receive FOLIFIRI chemotherapy comprise irinotecan hydrochloride IV 90 minute , leucovorin calcium 2 hour , fluorouracil IV continuously 46-48 hour , bevacizumab IV 30-90 minute . Treatment repeat 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 6 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must Karnofsky performance status &gt; = 60 % Patients must histological confirmation colorectal carcinoma Patients must colorectal tumor produce carcinoembryonic antigen ( CEA ) document either immunohistochemistry elevate serum CEA Patients enrol trial resection hepatic metastasis combine FOLFIRI FOLFOX [ +/ Bevacizumab ] , XELOX ; patient may receive maximum 12 cycle FOLFIRI FOLFOX [ +/ Bevacizumab ] , XELOX , include chemotherapy prior post hepatic resection Prior radiotherapy , immunotherapy , chemotherapy must complete 412 week prior patient entry study patient must recover expect acute side effect prior therapy Hemoglobin &gt; = 10 gm % ; patient may transfuse reach hemoglobin &gt; = 10 gm % White blood cell ( WBC ) &gt; = 4000/uL Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelets &gt; = 150,000/ul Patients may history prior malignancy patient diseasefree five year ; basal squamous cell skin cancer carcinoma situ cervix allow regardless diagnosis date Patients must prior history radiation therapy liver ( include 90Y microsphere therapy ) Patients must total bilirubin = &lt; 1.5 mg/dL Serum creatinine = &lt; 1.5 x upper limit normal ( ULN ) Patients must &lt; 40 % liver resect close completion hepatic resection ; verify retrospectively Serum human immunodeficiency virus ( HIV ) test hepatitis B surface antigen hepatitis C antibody test must negative Women childbearing potential must negative serum pregnancy test prior entry study must practice effective form contraception If patient previously receive murine chimeric antibody , serum antiantibody test must negative Computed tomography ( CT ) scan restaging do prior RIT must demonstrate evidence progressive disease The patient must see consultation radiation oncologist administer radiolabeled antibody therapy must inform potential risk side effect therapy , informed consent must document consultation note Patients receive radiation therapy great 50 % bone marrow Patients nonmalignant intercurrent illness ( example cardiovascular , pulmonary , central nervous system disease ) either poorly control currently available treatment severity investigator deem unwise enter patient protocol shall ineligible Chronic active hepatitis , cirrhosis , chemotherapy steatohepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>